Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ARCT

Arcturus Therapeutics (ARCT)

Arcturus Therapeutics Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARCT
DateTimeSourceHeadlineSymbolCompany
07/03/202508:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
25/02/202508:01Business WireArcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025NASDAQ:ARCTArcturus Therapeutics Holdings Inc
15/02/202500:30PR Newswire (US)European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccineNASDAQ:ARCTArcturus Therapeutics Holdings Inc
15/02/202500:00Business WireEuropean Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccineNASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/02/202500:30Business WireArcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair DesignateNASDAQ:ARCTArcturus Therapeutics Holdings Inc
31/01/202519:00Business WireMeiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19NASDAQ:ARCTArcturus Therapeutics Holdings Inc
31/01/202508:01Business WireArcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/01/202500:00Business WireArcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine TrialNASDAQ:ARCTArcturus Therapeutics Holdings Inc
07/01/202508:01Business WireArcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) DeficiencyNASDAQ:ARCTArcturus Therapeutics Holdings Inc
19/12/202408:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
17/12/202408:01Business WireArcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
27/11/202408:01Business WireArcturus Therapeutics to Attend Upcoming Investor ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
19/11/202412:00Business WireArcturus Therapeutics to Present at Jefferies London Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
14/11/202417:00Business WireMeiji Seika Pharma Announces Investment in ARCALIS, Inc.NASDAQ:ARCTArcturus Therapeutics Holdings Inc
12/11/202408:01Business WireArcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical TrialNASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/11/202408:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/11/202408:01Business WireArcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
01/11/202407:01Business WireArcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024NASDAQ:ARCTArcturus Therapeutics Holdings Inc
30/09/202422:00PR Newswire (US)Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-VaccinationNASDAQ:ARCTArcturus Therapeutics Holdings Inc
30/09/202422:00Business WireSelf-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-VaccinationNASDAQ:ARCTArcturus Therapeutics Holdings Inc
13/09/202422:15PR Newswire (US)Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika PharmaNASDAQ:ARCTArcturus Therapeutics Holdings Inc
13/09/202422:00Business WireJapan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika PharmaNASDAQ:ARCTArcturus Therapeutics Holdings Inc
03/09/202422:30Business WireArcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
28/08/202407:00Business WireArcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
13/08/202421:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
06/08/202406:50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARCTArcturus Therapeutics Holdings Inc
06/08/202406:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
06/08/202406:01Business WireArcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/08/202406:01Business WireArcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
19/07/202409:30Business WireArcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024NASDAQ:ARCTArcturus Therapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:ARCT